自身免疫性艾迪生病中的自身免疫性甲状腺疾病
基于挪威全国自身免疫病登记库的注册研究纳入912例自身免疫性艾迪生病(AAD)患者,442例(48%)诊断为自身免疫性甲状腺疾病,380例(42%)为自身免疫性甲状腺功能减退。诊断时20%为明显甲状腺功能减退、73%为亚临床甲状腺功能减退、7%甲状腺功能正常;32%甲状腺过氧化物酶抗体阴性。结论认为AAD中甲状腺功能减退的真实患病率低于现有文献报告,启动甲状腺素治疗需审慎考虑适应证。
要点
- 912例AAD患者中442例(48%)诊断为自身免疫性甲状腺疾病,380例(42%)为自身免疫性甲状腺功能减退。
- 203例诊断时有甲状腺功能检查者中,20%为明显甲状腺功能减退、73%为亚临床甲状腺功能减退、7%甲状腺功能正常。
- 78例(9%)诊断为Graves病,其中16例(21%)在Graves病发病前或缓解后诊断为自身免疫性甲状腺功能减退。
核心结论
- AAD中甲状腺功能减退的真实患病率低于现有文献报告,启动甲状腺素治疗需审慎考虑适应证。
- AAD合并Graves病患者的长期缓解率与近期报告的无AAD患者的长期随访结果相当。
研究设计与样本
- 基于挪威全国自身免疫病登记库的全国性注册研究,纳入912例注册的AAD患者。
主要发现
- 912例注册AAD患者中442例(48%)诊断为自身免疫性甲状腺疾病,380例(42%)为自身免疫性甲状腺功能减退。
- 203例诊断时具备甲状腺功能检查的患者中,20%为明显甲状腺功能减退、73%为亚临床甲状腺功能减退、7%甲状腺激素水平在正常范围。
- 32%的患者甲状腺过氧化物酶抗体阴性;98%接受左甲状腺素治疗,5%接受与碘塞罗宁或甲状腺提取物的联合治疗,1%未治疗观察。
- 78例(9%)诊断为Graves病,其中16例(21%)在Graves病发病前或缓解后诊断为自身免疫性甲状腺功能减退。
- 随访结束时,33%未用抗甲状腺药物或左甲状腺素而甲状腺激素水平正常,其余为活动性疾病(5%)、已接受消融治疗(41%)或已发生自身免疫性甲状腺功能减退(21%)。
临床怎么用
- 作者认为启动甲状腺素治疗需审慎考虑适应证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Autoimmune thyroid disease is the most common endocrine comorbidity in autoimmune Addison disease (AAD), but detailed investigations of prevalence and clinical course are lacking. OBJECTIVE: This work aimed to provide comprehensive epidemiological and clinical data on autoimmune thyroid disorders in AAD. METHODS: A nationwide registry-based study including 442 patients with AAD and autoimmune thyroid disease were identified through the Norwegian National Registry of Autoimmune Diseases. RESULTS: Of 912 registered AAD patients, 442 (48%) were diagnosed with autoimmune thyroid disease. A total of 380 (42%) had autoimmune hypothyroidism. Of the 203 with available thyroid function tests at time of diagnosis, 20% had overt hypothyroidism, 73% had subclinical hypothyroidism, and 7% had thyroid levels in the normal range. Negative thyroid peroxidase antibodies was found in 32%. Ninety-eight percent were treated with levothyroxine, 5% with combination therapy with liothyronine or thyroid extracts, and 1% were observed without treatment. Seventy-eight patients (9%) were diagnosed with Graves disease (GD), of whom 16 (21%) were diagnosed with autoimmune hypothyroidism either before onset or after remission of GD. At the end of follow-up, 33% had normal thyroid hormone levels without antithyroid-drugs or levothyroxine treatment. The remaining had either active disease (5%), had undergone ablative treatment (41%), or had developed autoimmune hypothyroidism (21%). CONCLUSION: The true prevalence of hypothyroidism in AAD is lower than reported in the current literature. Careful consideration of the indication to start thyroxin therapy is warranted. Long-term remission rates in GD patients with AAD are comparable to recent reports on long-term follow-up of patients without AAD.
引用
- Meling Stokland AE, Ueland G, Lima K, et al. Autoimmune Thyroid Disorders in Autoimmune Addison Disease. J Clin Endocrinol Metab. 2022. PMID: 35226748. doi:10.1210/clinem/dgac089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。